Loading
A phase 1/2 trial of Olaparib and Bevacizumab in ovarian cancer, small-cell lung cancer and gastric & gastro-oesophageal junction cancer, run by AstraZeneca, active and no longer recruiting.
A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. is a phase 1/2 interventional study registered as NCT02734004 by AstraZeneca, with 264 participants enrolled, started 2016-03-17 and due to reach its primary completion in 2021-09-17. Interventions recorded: Olaparib, MEDI4736 and Bevacizumab. Results have been posted on the registry.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
264 enrolled.
Figures from the ClinicalTrials.gov results section (first posted 2023-10-13), not from a publication
Source95% CI 81.12 to 97.82; Figures from the ClinicalTrials.gov results section (first posted 2023-10-13), not from a publication
SourceFigures from the ClinicalTrials.gov results section (first posted 2023-10-13), not from a publication
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Initial Stage Cohorts: Disease Control Rate (DCR) at Week 12primary | Initial Stage: Small Cell Lung Cancer | 38 | 28.9% | - | - | link |
| Initial Stage: Breast Cancer | 30 | 80% | ||||
| Initial Stage: Ovarian Cancer | 32 | 81.3% | ||||
| Initial Stage: Gastric Cancer | 39 | 25.6% | ||||
| Second Stage Cohort: Objective Response Rate (ORR)primary | Second Stage: Ovarian Cancer Expansion | 51 | 92.2% | - | - | link |
| Second Stage Cohorts: DCR at Week 24primary | Second Stage: Ovarian Cancer Triplet | 31 | 74.2% | - | - | link |
| Second Stage: Ovarian Cancer Doublet | 32 | 28.1% |
Shares PARP inhibitors, Olaparib, AstraZeneca, Ovarian cancer and the tag pipeline.
Shares PARP inhibitors, Olaparib, AstraZeneca and the tag pipeline.
Shares PARP inhibitors, Olaparib, AstraZeneca and the tag pipeline.
Shares IQVIA and the tag pipeline.
Shares PARP inhibitors, Olaparib, AstraZeneca and the tag pipeline.
Shares Bevacizumab, AstraZeneca, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares AstraZeneca, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
Shares PARP inhibitors, Olaparib and the tag pipeline.